%0 Journal Article
%T Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers
%A Anneleen Decock
%A Mat¨¦ Ongenaert
%A Jasmien Hoebeeck
%A Katleen De Preter
%A Gert Van Peer
%A Wim Van Criekinge
%A Ruth Ladenstein
%A Johannes H Schulte
%A Rosa Noguera
%A Raymond L Stallings
%A An Van Damme
%A Genevi¨¨ve Laureys
%A Jo£¿lle Vermeulen
%A Tom Van Maerken
%A Frank Speleman
%A Jo Vandesompele
%J Genome Biology
%D 2012
%I BioMed Central
%R 10.1186/gb-2012-13-10-r95
%X To identify genes silenced by promoter methylation, we first applied two independent genome-wide methylation screening methodologies to eight neuroblastoma cell lines. Specifically, we used re-expression profiling upon 5-aza-2'-deoxycytidine (DAC) treatment and massively parallel sequencing after capturing with a methyl-CpG-binding domain (MBD-seq). Putative methylation markers were selected from DAC-upregulated genes through a literature search and an upfront methylation-specific PCR on 20 primary neuroblastoma tumors, as well as through MBD- seq in combination with publicly available neuroblastoma tumor gene expression data. This yielded 43 candidate biomarkers that were subsequently tested by high-throughput methylation-specific PCR on an independent cohort of 89 primary neuroblastoma tumors that had been selected for risk classification and survival. Based on this analysis, methylation of KRT19, FAS, PRPH, CNR1, QPCT, HIST1H3C, ACSS3 and GRB10 was found to be associated with at least one of the classical risk factors, namely age, stage or MYCN status. Importantly, HIST1H3C and GNAS methylation was associated with overall and/or event-free survival.This study combines two genome-wide methylation discovery methodologies and is the most extensive validation study in neuroblastoma performed thus far. We identified several novel prognostic DNA methylation markers and provide a basis for the development of a DNA methylation-based prognostic classifier in neuroblastoma.Neuroblastoma (NB) is a neuroectodermal tumor that originates from precursor cells of the sympathetic nervous system and represents the most common extra-cranial solid tumor of early childhood. NB displays a highly variable clinical course, ranging from spontaneous regression to life-threatening disease [1].Despite advances in multimodal anti-cancer therapies, survival rates for children with aggressive NB remain disappointingly low. Survival rates vary widely, depending on clinical features, such as age
%U http://genomebiology.com/2012/13/10/R95